

Product Data Sheet

Product Name: ETC-501
Cat. No.: GC79476

Chemical Properties

Cas. No. 3094990-88-9


Formula $C_{26}H_{24}N_6O_2$ M.Wt 452.51

Solubility DMSO: 50 mg/mL (110.49 mM; Need ultrasonic) Storage Store at 4°C, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

ETC-501 is a blood-brain barrier-permeable, orally active, and selective MNK1 / MNK2 inhibitor, with

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

an IC₅₀ of 0.033 μ M against MNK1 and 0.111 μ M against MNK2. ETC-501 inhibits glioblastoma cell proliferation, impairs DNA damage repair function, delays cell cycle progression, and suppresses ribosome biogenesis. ETC-501 enhances Temozolomide -induced cellular senescence, attenuates the senescence-associated secretory phenotype, and increases cellular sensitivity to Navitoclax. ETC-501 is applicable to research related to glioblastoma [1].

In Vivo, ETC-501 (100 mg/kg; oral gavage; once daily; 21 days) enhances tumor cell senescence and attenuates the senescence-associated secretory phenotype when combined with TMZ in NSG mice bearing orthotopic or subcutaneous glioblastoma, and the additional combination with Navitoclax effectively eliminates senescent cells[1].

In Vitro, ETC-501 (0-20 μ M; 24 h) dose-dependently inhibits eIF4E phosphorylation and reduces Cyclin D1 protein levels in LN-229 and T98G glioblastoma cells[1]. ETC-501 (0-10 μ M) inhibits the viability of LN-229 and T98G glioblastoma cells with GI50 values of 4.035 μ M and 6.122 μ M, respectively, and reduces the tumor sphere-forming capacity and stem cell frequency of patient-derived GPCs[1]. ETC-501 (0-10 μ M; 4 h) impairs DNA synthesis in LN-229, T98G and U-87MG glioblastoma cells in a dose-dependent manner[1]. ETC-501 (8 h) impairs G1-to-S phase progression in Palbociclib -synchronized LN-229 and U-87MG glioblastoma cells[1]. ETC-501 (5-10 μ M; 14 days) induces cellular senescence in LN-229 and U-87MG glioblastoma cells[1]. ETC-501 (5-10 μ M; 10 days) reduces the levels of key inflammatory cytokines and chemokines, including IL-6, IL-8 and CCL2[1]. ETC-501 (10 μ M; 6 days) and TMZ drives LN-229 glioblastoma cells into a senescence priming state, and significantly enhances their sensitivity to Navitoclax -induced cell death and apoptosis[1].

References:

[1]. Nah GSS, et al. ETC-501 is a Brain Penetrant MNK Kinase Inhibitor that Potentiates TMZ-Induced Senescence and Sensitizes Glioblastoma Cells to Senolytic Therapy. Cancer Res. Published online January 22, 2026.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA